Original Article

Laboratory Survey of Antibiotic Nonsusceptibility among Streptococcus pneumoniae Isolates in South Carolina, 1998 versus 2000

Authors: Daniel G. Dauner, MSPH, James J. Gibson, MD, MPH, Dixie F. Roberts, RN, MPH, George S. Kotchmar, MD

Abstract

Background In 1998, the South Carolina Department of Health and Environmental Control surveyed clinical microbiology laboratories statewide to determine the prevalence of antibiotic nonsusceptibility among isolates of Streptococcus pneumoniae. A follow-up study was conducted in 2001. Methods A cross-sectional study was conducted to estimate the prevalence of penicillin nonsusceptibility (PCN-N), extended-spectrum cephalosporin nonsusceptibility (ESC-N), and levofloxacin nonsusceptibility (LEV-N) in South Carolina. A standardized questionnaire was mailed to 89 laboratories. Results The prevalence of penicillin intermediate resistance increased from 1998 (17.6%) to 2000 (20.9%, &khgr;2P = 0.008). Furthermore, the prevalence of PCN-N increased from 1998 (34.5%) to 2000 (38.4%, &khgr;2P = 0.01). The prevalence of ECN-N decreased from 1998 (19.1%) to 2000 (17.7%), but the difference was not significant (&khgr;2P = 0.25). Conclusion The laboratory survey was a low-cost method of estimating the change in prevalence of antibiotic nonsusceptibility, and it emphasizes regional surveillance because the prevalence of antibiotic nonsusceptibility varied geographically.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Centers for Disease Control and Prevention. Defining the public health impact of drug-resistantStreptococcus pneumoniae: Report of a working group. MMWR Recomm Rep 1996; 45 (RR-1 Suppl): 1–20.
 
2. Centers for Disease Control and Prevention. Assessment of national reporting of drug-resistantStreptococcus pneumoniae–United States, 1995–1996. MMWR Morb Mortal Wkly Rep 1996; 45: 947–949.
 
3. Macias EA, Mason EO Jr, Ocera HY, et al. Comparison of E test with standard broth microdilution for determining antibiotic susceptibilities of penicillin-resistant strains of Streptococcus pneumoniae. J Clin Microbiol 1994; 32: 430–432.
 
4. Spika JS, Facklam RR, Plikaytis BD, et al. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987: The Pneumococcal Surveillance Working Group. J Infect Dis 1991; 163: 1273–1278.
 
5. Nuorti JP, Butler JC, Crutcher JM, et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med 1998; 338: 1861–1868.
 
6. Block SL, Harrison CJ, Hedrick JA, et al. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: Risk factors, susceptibility patterns and antimicrobial management. Pediatr Infect Dis J 1995; 14: 751–759.
 
7. Centers for Disease Control and Prevention. Prevalence of penicillin-resistant Streptococcus pneumoniae: Connecticut, 1992–1993. MMWR Morb Mortal Wkly Rep 1994; 43: 216–217, 223.
 
8. McGowan JE Jr, Metchock BG. Penicillin-resistant pneumococci: An emerging threat to successful therapy. J Hosp Infect 1995; 30 (Suppl): 472–482.
 
9. Poole MD. Otitis media complications and treatment failures: Implications of pneumococcal resistance. Pediatr Infect Dis J 1995; 14 (4 Suppl): S23–S26.
 
10. Duchin JS, Breiman RF, Diamond A, et al. High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community. Pediatr Infect Dis J 1995; 14: 745–750.
 
11. Breiman RF, Butler JC, Tenover FC, et al. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994; 271: 1831–1835.
 
12. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: Management and surveillance in an era of pneumococcal resistance—a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999; 18: 1–9.
 
13. Office of Research and Statistics, South Carolina State Budget and Control Board. 1996 Statistical Abstract. Columbia, Office of Research and Statistics, South Carolina State Budget and Control Board, 1996.
 
14. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report: Emerging Infections Program Network— Streptococcus pneumoniae, 2000. Atlanta, GA, Centers for Disease Control and Prevention. Available at:http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu00.pdf. Accessed July 2, 2003.
 
15. Quale J, Landman D, Ravishankar J, et al. Streptococcus pneumoniae, Brooklyn, New York: Fluoroquinolone resistance at our doorstep. Emerg Infect Dis 2002; 8: 594–597.
 
16. Heffernan R, Henning K, Labowitz A, et al. Laboratory survey of drug-resistant Streptococcus pneumoniae in New York City, 1993–1995. Emerg Infect Dis 1998; 4: 113–116.